Even casual fans of Golf can easily see that the sport is enjoying widespread global popularity as well as very favorable demographic trends. These trends in the golf industry may help explain the ever-increasing popularity of the Golf Core Grip Workout System and mobile app sold by LifeApps Digital Media, Inc. (OTCQB – LFAP - $0.08 – Spec Buy).

Considering the success of some of the programs in Israel in treating cancer patients with cannabis, Nuvilex Inc.’s (OTCQB – NVLX - $0.16 – Spec Buy) subsidiary, Medical Marijuana Sciences, Inc. may elect to emulate some of that country’s initiatives.

The poor side effect profile for an already approved malaria drug serves as a major boost to Plandai Biotechnology Inc.’s (OTCQB – PLPL - $0.47 - Spec Buy) new malaria treatment efforts.

By 2015 many industry analysts project that the majority of web traffic in the U.S. will be mobile-based, rather than computer-based web traffic. This shift plays directly into the sweet spot of LifeApps Digital Media, Inc

Based on recent grants, , Nuvilex appears well positioned to be eligible to receive research lucrative grants or funding from other partner firms seeking to study the efficacy of live-cell encapsulation-based therapies used for oncology therapy, with medical marijuana.

A 2007 study in the Journal of the American College of Nutrition looked at the effects of green tea catechins, specifically epigallocatechin gallate (EGCG), on subjects suffering from colds and flu. Over 32% fewer people in the green tea group experienced no cold and flu symptoms compared to the placebo group, and nearly 23% experienced less symptoms lasting fewer days. These results come as no surprise as EGCG and green tea catechins are found to be an inhibitor of common cold adenovirus.

Recent events and future milestones serve to benefit Nuvilex as the stars align for management and its shareholders.